|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
SELECT PUBLICATIONS
Doyle JJ et al. Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. J Clin Oncol 2005;23:8597-605. Abstract
Gradishar W et al. A randomized phase 2 trial of qw or q3w ABI-007 (ABX) vs q3W solvent-based docetaxel (TXT) as first-line therapy in metastatic breast cancer (MBC). San Antonio Breast Cancer Symposium 2006;Abstract 46.
Jones SE et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin
Oncol 2006;24:5381-7. Abstract
Linden HM et al. PET FES measures in vivo pharmacodynamics of endocrine therapy. Proc ASCO 2007;Abstract 14110.
Linden HM et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 2006;24(18):2793-9. Abstract
Mankoff DA et al. [18F]fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med 2001;42(4):679-84. Abstract
Sledge G et al. Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer. Proc ASCO 2007;Abstract 1013.
 |
 |
EDITOR'S NOTE
Survivors
Neil Love, MD
- Select publications
INTERVIEWS
Ian E Smith, MD
- Select publications
Charles L Vogel, MD
- Select publications
Sandra M Swain, MD
- Select publications
Paul E Goss, MD, PhD
- Select publications
Hannah M Linden, MD
- Select publications
Breast Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
 |
 |
